尤斯泰金單抗 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "尤斯泰金單抗" in Chinese language version.

refsWebsite

Global rank Chinese rank

22web.archive.org

1^st place

8nih.gov

4^th place

5^th place

6doi.org

2^nd place

23^rd place

5fda.gov

447^th place

581^st place

2europa.eu

68^th place

209^th place

2drugs.com

399^th place

208^th place

2semanticscholar.org

11^th place

332^nd place

1medicines.org.uk

3,823^rd place

3,456^th place

1healio.com

low place

1nps.org.au

low place

1stelarainfo.com

low place

1idsk.com

low place

1who.int

195^th place

179^th place

1drugbank.ca

4,294^th place

8,905^th place

1empr.com

low place

1pbs.gov.au

low place

1fdanews.com

low place

doi.org

Cingoz O. Ustekinumab. mAbs. 2009, 1 (3): 216–221. PMC 2726595 . PMID 20069753. doi:10.4161/mabs.1.3.8593.
Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. The Lancet. Neurology. September 2008, 7 (9): 796–804. PMID 18703004. S2CID 20290673. doi:10.1016/S1474-4422(08)70173-X.
Reddy M, Davis C, Wong J, Marsters P, Pendley C, Prabhakar U. Modulation of CLA, IL-12R, CD40L, and IL-2Ralpha expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275. Cellular Immunology. May 2007, 247 (1): 1–11. PMID 17761156. doi:10.1016/j.cellimm.2007.06.006.
Toussirot E. The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases. Inflammation & Allergy - Drug Targets. April 2012, 11 (2): 159–168. PMID 22280236. doi:10.2174/187152812800392805.
Weber J, Keam SJ. Ustekinumab. BioDrugs. 2009, 23 (1): 53–61. PMID 19344192. S2CID 265771199. doi:10.2165/00063030-200923010-00006.
Koutruba N, Emer J, Lebwohl M. Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis. Therapeutics and Clinical Risk Management. April 2010, 6: 123–141. PMC 2857612 . PMID 20421912. doi:10.2147/tcrm.s5599 .

drugbank.ca

drugbank.ca. [2019-10-04]. （原始内容存档于2020-01-31）.

drugs.com

Ustekinumab. The American Society of Health-System Pharmacists. [2017-01-08]. （原始内容存档于2017-02-02）.
FDA Issues Complete Response Letter to Centocor for Ustekinumab Biologic License Application. Drugs.com (新闻稿). Centocor. 2009-09-25 [2020-04-06]. （原始内容存档于2020-04-06）.

empr.com

Stelara approved for moderate to severe psoriasis. Sept 2009. 2009-09-26 [2010-07-06]. （原始内容存档于2015-09-20）.

europa.eu

ema.europa.eu

Stelara EPAR. European Medicines Agency (EMA). 2018-09-17 [2020-04-06]. （原始内容存档于2020-04-06）.
Uzpruvo: Pending EC decision. European Medicines Agency (EMA). 2023-11-10 [2023-11-13]. （原始内容存档于2023-11-10）.

fda.gov

accessdata.fda.gov

CENTER FOR DRUG EVALUATION AND RESEARCH Approval Package for: APPLICATION NUMBER: 1252610rigls103 (PDF). CENTER FOR DRUG EVALUATION AND RESEARCH. 2013-09-20 [2024-01-03]. （原始内容存档 (PDF)于2024-01-03）.
Drug Approval Package: Stelara (Ustekinumab) Injection NDA #125261. U.S. Food and Drug Administration (FDA). 1999-12-24 [2020-04-06]. （原始内容存档于2020-04-06）.
Stelara (ustekinumab) Injection NDA #761044. U.S. Food and Drug Administration (FDA). 2018-01-12 [2020-04-06]. （原始内容存档于2020-04-06）.
Stelara: FDA-Approved Drugs. U.S. Food and Drug Administration (FDA). [2020-04-06]. （原始内容存档于2020-10-20）.

fda.gov

FDA Approves Interchangeable Biosimilar for Multiple Inflammatory Diseases. U.S. Food and Drug Administration (新闻稿). 2023-10-31 [2023-11-13]. （原始内容存档于2023-11-13）. 本文含有此來源中屬於公有领域的内容。

fdanews.com

Janssen's Stelara Gets FDA Approval for Ulcerative Colitis. FDA News. [2019-10-31]. （原始内容存档于2020-01-13）.

healio.com

EC approves expanded use of Stelara for moderately to severely active ulcerative colitis. Healio.com. [2019-09-26]. （原始内容存档于2019-09-09）.

idsk.com

news.idsk.com

Medarex to Receive Milestone Payment for Approval of Stelara (Ustekinumab) for the Treatment of Moderate to Severe Plaque Psoriasis. [2008-12-16]. （原始内容存档于2013-08-01）.

medicines.org.uk

Stelara 45 mg solution for injection (vials) - Summary of Product Characteristics (SmPC). (emc). 2020-02-27 [2020-04-06]. （原始内容存档于2020-04-06）.

nih.gov

ncbi.nlm.nih.gov

Cingoz O. Ustekinumab. mAbs. 2009, 1 (3): 216–221. PMC 2726595 . PMID 20069753. doi:10.4161/mabs.1.3.8593.
Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. The Lancet. Neurology. September 2008, 7 (9): 796–804. PMID 18703004. S2CID 20290673. doi:10.1016/S1474-4422(08)70173-X.
Reddy M, Davis C, Wong J, Marsters P, Pendley C, Prabhakar U. Modulation of CLA, IL-12R, CD40L, and IL-2Ralpha expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275. Cellular Immunology. May 2007, 247 (1): 1–11. PMID 17761156. doi:10.1016/j.cellimm.2007.06.006.
Toussirot E. The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases. Inflammation & Allergy - Drug Targets. April 2012, 11 (2): 159–168. PMID 22280236. doi:10.2174/187152812800392805.
Weber J, Keam SJ. Ustekinumab. BioDrugs. 2009, 23 (1): 53–61. PMID 19344192. S2CID 265771199. doi:10.2165/00063030-200923010-00006.
Koutruba N, Emer J, Lebwohl M. Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis. Therapeutics and Clinical Risk Management. April 2010, 6: 123–141. PMC 2857612 . PMID 20421912. doi:10.2147/tcrm.s5599 .

dailymed.nlm.nih.gov

Stelara- ustekinumab injection, solution Stelara- ustekinumab solution. DailyMed. 2020-03-24 [2020-04-06]. （原始内容存档于J2019-07-02）.

pubmed.ncbi.nlm.nih.gov

Bianca Maria Wittig, Bianca Maria. Drug evaluation: CNTO-1275, a mAb against IL-12/IL-23p40 for the potential treatment of inflammatory diseases. Current opinion in investigational drugs. November 2007, 8 (11): 947–54 [2024-01-03]. （原始内容存档于2024-01-03）.

nps.org.au

Ustekinumab (Stelara) PBS listed for severe Crohn's disease. NPS Medicinewise. 2017-10-26 [2019-10-04]. （原始内容存档于2019-04-18）.

pbs.gov.au

2017-09-12. [2019-10-04]. （原始内容存档于2021-03-15）.

semanticscholar.org

api.semanticscholar.org

Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. The Lancet. Neurology. September 2008, 7 (9): 796–804. PMID 18703004. S2CID 20290673. doi:10.1016/S1474-4422(08)70173-X.
Weber J, Keam SJ. Ustekinumab. BioDrugs. 2009, 23 (1): 53–61. PMID 19344192. S2CID 265771199. doi:10.2165/00063030-200923010-00006.

stelarainfo.com

Important Safety Information. Stelara (ustekinumab). Janssen Biotech. 2019-05-22 [2010-12-31]. （原始内容存档于2021-03-29）.

web.archive.org

FDA Approves Interchangeable Biosimilar for Multiple Inflammatory Diseases. U.S. Food and Drug Administration (新闻稿). 2023-10-31 [2023-11-13]. （原始内容存档于2023-11-13）. 本文含有此來源中屬於公有领域的内容。
Ustekinumab (Stelara) Use During Pregnancy. Drugs.com. 2019-11-26. （原始内容存档于2020-05-22）使用|archiveurl=需要含有|url= (帮助). 已忽略未知参数|-04-06url= (帮助); 缺少或|url=为空 (帮助);
Stelara 45 mg solution for injection (vials) - Summary of Product Characteristics (SmPC). (emc). 2020-02-27 [2020-04-06]. （原始内容存档于2020-04-06）.
Stelara- ustekinumab injection, solution Stelara- ustekinumab solution. DailyMed. 2020-03-24 [2020-04-06]. （原始内容存档于J2019-07-02）.
Stelara EPAR. European Medicines Agency (EMA). 2018-09-17 [2020-04-06]. （原始内容存档于2020-04-06）.
Ustekinumab. The American Society of Health-System Pharmacists. [2017-01-08]. （原始内容存档于2017-02-02）.
EC approves expanded use of Stelara for moderately to severely active ulcerative colitis. Healio.com. [2019-09-26]. （原始内容存档于2019-09-09）.
Ustekinumab (Stelara) PBS listed for severe Crohn's disease. NPS Medicinewise. 2017-10-26 [2019-10-04]. （原始内容存档于2019-04-18）.
Important Safety Information. Stelara (ustekinumab). Janssen Biotech. 2019-05-22 [2010-12-31]. （原始内容存档于2021-03-29）.
Bianca Maria Wittig, Bianca Maria. Drug evaluation: CNTO-1275, a mAb against IL-12/IL-23p40 for the potential treatment of inflammatory diseases. Current opinion in investigational drugs. November 2007, 8 (11): 947–54 [2024-01-03]. （原始内容存档于2024-01-03）.
FDA Issues Complete Response Letter to Centocor for Ustekinumab Biologic License Application. Drugs.com (新闻稿). Centocor. 2009-09-25 [2020-04-06]. （原始内容存档于2020-04-06）.
Medarex to Receive Milestone Payment for Approval of Stelara (Ustekinumab) for the Treatment of Moderate to Severe Plaque Psoriasis. [2008-12-16]. （原始内容存档于2013-08-01）.
Application to Add Ustekinumab to the World Health Organization’s Essential Medicines List for the treatment of severe psoriasis (PDF). Medicines Working Group of The International League of Dermatological Societies. [2024-01-03]. （原始内容存档 (PDF)于2024-01-03）. In addition, in 2013, the US Food and Drug Administration (FDA) approved the use of ustekinumab for the treatment of psoriatic arthritis
CENTER FOR DRUG EVALUATION AND RESEARCH Approval Package for: APPLICATION NUMBER: 1252610rigls103 (PDF). CENTER FOR DRUG EVALUATION AND RESEARCH. 2013-09-20 [2024-01-03]. （原始内容存档 (PDF)于2024-01-03）.
drugbank.ca. [2019-10-04]. （原始内容存档于2020-01-31）.
Stelara approved for moderate to severe psoriasis. Sept 2009. 2009-09-26 [2010-07-06]. （原始内容存档于2015-09-20）.
Drug Approval Package: Stelara (Ustekinumab) Injection NDA #125261. U.S. Food and Drug Administration (FDA). 1999-12-24 [2020-04-06]. （原始内容存档于2020-04-06）.
Stelara (ustekinumab) Injection NDA #761044. U.S. Food and Drug Administration (FDA). 2018-01-12 [2020-04-06]. （原始内容存档于2020-04-06）.
2017-09-12. [2019-10-04]. （原始内容存档于2021-03-15）.
Janssen's Stelara Gets FDA Approval for Ulcerative Colitis. FDA News. [2019-10-31]. （原始内容存档于2020-01-13）.
Stelara: FDA-Approved Drugs. U.S. Food and Drug Administration (FDA). [2020-04-06]. （原始内容存档于2020-10-20）.
Uzpruvo: Pending EC decision. European Medicines Agency (EMA). 2023-11-10 [2023-11-13]. （原始内容存档于2023-11-10）.

who.int

cdn.who.int

Application to Add Ustekinumab to the World Health Organization’s Essential Medicines List for the treatment of severe psoriasis (PDF). Medicines Working Group of The International League of Dermatological Societies. [2024-01-03]. （原始内容存档 (PDF)于2024-01-03）. In addition, in 2013, the US Food and Drug Administration (FDA) approved the use of ustekinumab for the treatment of psoriatic arthritis